LeonaBio (LONA) Other Non Operating Income (2019 - 2026)
LeonaBio (LONA) posted quarterly Other Non Operating Income of $586000.0 for Q1 2026, up 49.11% year-over-year from $393000.0 in Q1 2025, and up 129.8% quarter-over-quarter from $255000.0 in Q4 2025.
LeonaBio (LONA) Other Non Operating Income (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Other Non Operating Income for 8 consecutive years, with $586000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 49.11% year-over-year to $586000.0; the TTM figure through Mar 2026 stood at $1.4 million (down 52.45% YoY), while the FY2025 annual figure was $1.2 million, down 68.8% from the prior year.
- Other Non Operating Income improved to $586000.0 in Q1 2026 per LONA's latest filing, from $255000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $2.1 million in Q3 2023 and bottomed at $173000.0 in Q1 2022.
- Historically, Other Non Operating Income has averaged $978647.1 across 5 years, with a median of $880000.0 in 2024.
- Annual changes were most pronounced in 2022 — Other Non Operating Income soared 1419.42% — and 2025, when it slumped 72.2%.
- LeonaBio's Other Non Operating Income stood at $1.6 million in 2022, then advanced by 10.48% to $1.7 million in 2023, then plunged by 67.44% to $563000.0 in 2024, then slumped by 54.71% to $255000.0 in 2025, then soared by 129.8% to $586000.0 in 2026.
- Business Quant data shows LONA's Other Non Operating Income at $586000.0 in Q1 2026, $255000.0 in Q4 2025, and $263000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | LeonaBio | 180.91 Mn | 129.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 586,000.00 |
| Dec 31, 2025 | 255,000.00 |
| Sep 30, 2025 | 263,000.00 |
| Jun 30, 2025 | 325,000.00 |
| Mar 31, 2025 | 393,000.00 |
| Dec 31, 2024 | 563,000.00 |
| Sep 30, 2024 | 880,000.00 |
| Jun 30, 2024 | 1.17 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Dec 31, 2023 | 1.73 Mn |
| Sep 30, 2023 | 2.07 Mn |
| Jun 30, 2023 | 2.04 Mn |
| Mar 31, 2023 | 1.79 Mn |
| Dec 31, 2022 | 1.57 Mn |
| Sep 30, 2022 | 985,000.00 |
| Jun 30, 2022 | 493,000.00 |
| Mar 31, 2022 | 173,000.00 |
| Dec 31, 2021 | 103,000.00 |
| Sep 30, 2021 | 73,000.00 |
| Jun 30, 2021 | 74,000.00 |